ENERZAIR BREEZHALER

novartis pharmaceuticals canada inc🇨🇦 Health Canada

Approval Id: 4c44e5101b80b695
Drug Approval Canada Name: ENERZAIR BREEZHALER
Product Name: ENERZAIR BREEZHALER
Status: Marketed
Status Date: 2020-11-05
Original Market Date: 2020-11-05
Din: 02501244
Drug Class: Human
Dosage Form: Capsule
Route Of Administration: Inhalation
Schedule: Prescription
Ahfs: 12:12.08.12
Atc Original: R03AL12 INDACATEROL, GLYCOPYRRONIUM BROMIDE AND MOMETASONE
Atc Name: r 03 al 12
Aig Number: 0362336001
Company Name: novartis pharmaceuticals canada inc
Company Address: 100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1

MOMETASONE FUROATE

160 MCG

INDACATEROL (INDACATEROL ACETATE)

150 MCG

GLYCOPYRRONIUM (GLYCOPYRROLATE)

50 MCG

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

4c44e5101b80b695

Type

Standard